The insider sales are too small to be informative on their own, but the cluster's timing with earnings and the massive shelf registration signals that insiders are not buying the dip. The $400M shelf overhang and going-concern warning dominate the narrative. Monitor for any ATM drawdown or further insider selling; the stock is likely to remain under pressure until the capital raise is resolved.
Price Chart
Executive Summary
Karyopharm's CEO, CAO, and EVP/CLO sold a total of $23K in open-market shares on May 14, 2026, the same day the company reported Q1 earnings that beat EPS consensus by 29% but included a going-concern warning and a $400M shelf filing. The sales are trivial at 0.01% of market cap and likely liquidity-driven following equity grants, but the cluster's timing with earnings and the massive dilution overhang from the shelf registration creates a bearish context.
Key Financial Metrics
Key Facts
- CEO Richard Paulson sold 2,203 shares at $9.50 for $20,929 on May 14, 2026.
- CAO Kristin Abate sold 53 shares at $9.50 for $504 on May 14, 2026.
- EVP/CLO Michael Mano sold 266 shares at $9.50 for $2,527 on May 14, 2026.
- Total open-market sales: $23,959, representing 0.01% of KPTI's $201M market cap.
- All three insiders also received non-cash equity grants (shares) on May 13, 2026, totaling 5,741 shares at $0.
- The sales occurred one day after Q1 2026 earnings (revenue $35.1M, net loss -$22.4M, EPS beat consensus by 29%) and 11 days after a $400M shelf registration was filed.
- The $400M shelf (including a $100M ATM) represents ~200% of market cap; the company has a going-concern warning and cash runway only into late Q3 2026.
- The insider sales are trivial in dollar terms but cluster with earnings and a dilutive capital raise, per cross-filing actuarial amplifiers.
Financial Impact
Open-market sales of $23,959 (0.01% of market cap) are immaterial in isolation, but the context of a $400M shelf (200% dilution) and going-concern warning is highly material.
Risk Factors
- Massive dilution from the $400M shelf registration (200% of market cap) if fully utilized.
- Going-concern warning with cash runway only into late Q3 2026, forcing a dilutive capital raise.
- Phase 3 SENTRY myelofibrosis trial missed a co-primary endpoint, reducing pipeline optionality.
- Insider sales, though small, may signal lack of confidence in the near-term outlook.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KPTI-1778875595275 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access